MAPS-2 (IFCT-1501): Nivolumab ± Ipilimumab in Recurrent Malignant Pleural Mesothelioma

June 2-6, 2017; Chicago, Illinois
Nivolumab with and without ipilimumab was associated with 12-week disease control rates > 40% and median OS > 10 months in patients who progressed after 1-2 lines of chemotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 671 KB
Released: June 9, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Phase I data on mesothelin-targeted CAR T-cell therapy with or without pembrolizumab in malignant pleural cancers, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 24, 2021

From Clinical Care Options (CCO), a video webinar on fundamentals of CAR T-cell therapy for pharmacy and managed care professionals

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2021 Expired: September 23, 2022

Phase I/II trial of mobocertinib for EGFR ex20ins+ advanced NSCLC in cohort of patients with disease progression after initial disease control on EGFR TKI therapy, from WCLC 2021 by Clinical Care Options (CCO)

Released: September 23, 2021

Initial analysis of amivantamab in patients with METex14+ metastatic or unresectable NSCLC from phase I CHRYSALIS trial, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue